Nishinomiya, Japan

Sinji Ueda

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharmaceuticals Company Limited. Active years: 1987.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sinji Ueda. Retrieved from https://idiyas.com/inventor/sinji-ueda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sinji Ueda: Innovator in Antibacterial Compounds

Introduction

Sinji Ueda is a notable inventor based in Nishinomiya, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents. His work has implications for the prevention and treatment of bacterial infectious diseases.

Latest Patents

Ueda holds a patent for cephem compounds, which are represented by a specific general formula. These compounds, characterized by various substituents, are valuable as antibacterial agents. They are especially useful as oral drugs, providing effective treatment options for bacterial infections. His patent is a testament to his innovative approach in pharmaceutical chemistry.

Career Highlights

Sinji Ueda is associated with Sumitomo Pharmaceuticals Company Limited, where he has been instrumental in advancing research and development in the pharmaceutical sector. His expertise in creating effective antibacterial compounds has positioned him as a key figure in his field.

Collaborations

Ueda has collaborated with notable colleagues, including Hirotada Yamada and Naruhito Masai. These partnerships have fostered a collaborative environment that enhances the innovation process within their projects.

Conclusion

Sinji Ueda's contributions to the field of antibacterial compounds highlight his role as an influential inventor. His work continues to impact the pharmaceutical industry positively, paving the way for new treatments against bacterial infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…